Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 13/20 | 0.70 |
| ▸ | AR | P10275 | 12/20 | 0.70 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4213506 | 0.84 | PGR (0.65) | PGRARNR3C2CYP19A1LMNA | |
| SCHEMBL12998959 | 0.83 | PGR (1.00) | PGRARNR3C2CYP19A1LMNA | |
| SCHEMBL12943045 | 0.83 | PGR (1.00) | PGRARNR3C2CYP19A1LMNA | |
| SCHEMBL16572801 | 0.83 | PGR (1.00) | PGRARNR3C2CYP19A1LMNA | |
| SCHEMBL4214248 | 0.82 | PGR (0.68) | PGRARNR3C2CYP19A1LMNA | |
| SCHEMBL12942725 | 0.82 | PGR (0.75) | PGRARNR3C2CYP19A1LMNA | |
| SCHEMBL13556648 | 0.81 | PGR (0.64) | PGRARNR3C2CYP19A1LMNA | |
| SCHEMBL13768841 | 0.81 | PGR (0.66) | PGRARNR3C2CYP19A1LMNA | |
| SCHEMBL12904794 | 0.81 | AR (0.68) | PGRARNR3C2CYP19A1 | |
| SCHEMBL10089121 | 0.81 | PGR (0.68) | PGRARNR3C2CYP19A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207150-B2 | 17β-cyano-19-nor-androst-4-ene derivative, its use and medicaments comprising the derivative | Bayer Pharma AG (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20090048217-A1 | 17Beta-CYANO-19-NOR-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048217-A1 | 17Beta-CYANO-19-NOR-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | HSD17B11, HSD17B7, NR5A1 | PGR 87/4885AR 109/4885NR3C2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.